Antimicrobial susceptibility pattern of gram-negative aerobic isolates from intensive care units in Saudi Arabia; A multicenter study

Saudi Medical Journal

Volumn 18, Issue 5, 1997, Pages 471-475

  Osoba, Abimbola O ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Antimicrobial susceptibilities; Gram negative aerobic isolates; ICU's; Saudi Arabia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAMASE; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEZLOCILLIN; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SPECIES DIFFERENTIATION;

EID: 0030680264     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Neu HC, Jones RN, Emerging trend s in gram negative resistance: A new concern for critical care medicine (Foreward). Diagn. Microbiol. Infect. Dis. 1992; 15: 15.
2. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: 2nd ed. M7-A2. National Committee for Clinical laboratory Standards, Villanova. Pa. 1990.
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: 4th ed. M2-A4. National Committee for Clinical Laboratory Standards. Villanova. Pa. 1990
4. Gasparetto A, Delogu G, Ceftazidime. as a single antibiotic in the treatment of multi-resistant Gram-negative isolates in intensive care. Journal of Antimicrobial Chemotherapy. 1983; 12: Suppl A. 171-175.
5. Pierson CL and Friedman BA. Comparison of susceptibility to β-lactam Antimicrobial agent among bacteria isolated from intensive care units. Dias. Microbiol. Infect. Dis. 1992; 15: 195-305.
6. Wiedeman B, Kliebe C, Kreksen M. The epidemiology of β-lactamases. J Antimicrob Chemother 1989; 24: Suppl. B, 1-22.
7. Philipon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrobial agents and chemotherapy. 1989; 33: 1131-1136.
8. Matthew M. Plasmid - mediated β-lactamases of gram-negative bacteria: properties and distribution. Journal of Antimicrobial Chemotherapy. 1979; 5: 349-358.
9. Osoba A.O. Recent advances in antibiotic resistant gram-negative bacilli: Pan 1. Postgraduate Doctor (Middle East). 1995; 18: 220-230.
10. Shah P M, Asanger R, Kahan F, Incidence of multi-resistance in gram-negative aerobes from intensive care units of ten German hospitals. Scandinavian Journal of Infectious Diseases. 1991: Suppl. 78: 22-34.
11. Syndman DR. Clinical implications of multi-drug resistance in the intensive care unit. Scandinavian Journal of Infectious Diseases. 1991: Suppl 78: 54-63.
12. Liu PYE, Gur D, Hall LMC, Livermore DM. Survey of the prevalence of β-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital J Antimicrob. Chemother. 1992; 30: 429-447.
13. Verbist L. Incidence of multi-resistance in gram-negative bacterial isolates from Intensive Care Units in Belgium: A Surveillance Study. Scand J Infect Dis 1991: Suppl 78: 45-53.
14. Verbist L. A Belgian multicenter in-vitro study of ofloxacin. J antimicrob. Chemother. 1988; 22: 35-43.
15. Jacoby GA, Archer GI, New mechanisms of bacterial resistance to antimicrobial agents. NEJM 1991; 324: 601-612.
16. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-1073.